PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Cancer cells evade immune responses through mechanisms like PD-L1 overexpression, which exhausts CD8+ T cells.
• While PD-1/PD-L1 checkpoint blockade antibodies show clinical success, improved response rates necessitate novel strategies.

Purpose of the Study:

• To engineer cellular nanovesicles (NVs) presenting PD-1 receptors to disrupt the PD-1/PD-L1 immune inhibitory axis.
• To evaluate the efficacy of these PD-1 NVs, alone and in combination with 1-methyl-tryptophan, in enhancing antitumor responses.

Main Methods:

• Engineered cellular nanovesicles (NVs) were developed to display PD-1 receptors on their surface.
• The binding of PD-1 NVs to PD-L1 on melanoma cells was assessed, along with their circulation time.
• 1-methyl-tryptophan, an indoleamine 2,3-dioxygenase inhibitor, was loaded into PD-1 NVs for synergistic immune modulation.

Main Results:

• PD-1 NVs demonstrated effective binding to PD-L1 on melanoma cancer cells and exhibited prolonged circulation.
• Co-administration with 1-methyl-tryptophan synergistically disrupted immune tolerance pathways within the tumor microenvironment.
• PD-1 NVs significantly increased the infiltration of CD8+ T cells at the tumor margin, leading to direct tumor regression.

Conclusions:

• Engineered PD-1 NVs represent a promising approach to overcome immune suppression in cancer.
• This strategy effectively disrupts the PD-1/PD-L1 axis and enhances T cell-mediated antitumor immunity.
• PD-1 NVs hold potential for improving therapeutic outcomes in melanoma and other cancers.